............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
WorldHeart Announces Levacor VAD Implant
at Inova Fairfax Hospital, Virginia
SALT LAKE CITY, April 13, 2010 /PRNewswire via COMTEX/ --World
Heart Corporation (WorldHeart; Nasdaq: WHRT), a developer of
mechanical circulatory systems, announced today that Inova
Fairfax Hospital (Inova) in Falls Church, Virginia has
successfully implanted its first Levacor(TM) Ventricular Assist
Device (VAD). Inova Fairfax has extensive experience in the VAD
field and is the third implanting site nationwide in the Levacor
VAD Bridge-To-Transplant (BTT) Study. This is the fifth implant
with the Levacor VAD since the inception of the BTT clinical
study.
Dr. Nelson Burton, Surgical Director of Heart Transplant and
Mechanical Circulatory Support and Inova Fairfax's surgical
co-Principal Investigator for the BTT clinical study commented,
"We are pleased to be an active center in the Levacor BTT study.
We believe that mechanical circulatory support has a significant
role in the treatment of heart failure and, therefore, look
forward to further advancing VAD options for our patients. "
Mr. J. Alex Martin, WorldHeart's President and Chief Executive
Officer added, "Inova Fairfax has consistently been recognized
as one of the nation's best hospitals, specifically in the
treatment of heart failure. We are enthusiastic about the study
collaboration with Inova Fairfax's clinicians in the service of
their patients and in the potential for expansion of VAD
treatment opportunities. "
About the Levacor VAD and World Heart Corporation
The Levacor VAD is the only fully magnetically levitated,
bearingless, implantable centrifugal pump to move into clinical
trial. By using magnetic levitation to fully suspend a spinning
rotor, the Levacor VAD's only moving part, the pump is designed
to eliminate wear and to provide unobstructed clearances for
blood flow across a wide range of operation.
WorldHeart is a developer of mechanical circulatory support
systems based in Salt Lake City, Utah with additional facilities
in Oakland, California, USA. WorldHeart's registered office is
in Delaware, USA.
Any forward-looking statements in this release are made pursuant
to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include all statements
relating to WorldHeart's BTT clinical study of the Levacor VAD,
strategic direction, increase in shareholder value, access to
investment capital, its clinical development programs and the
product pipeline, and the growth of WorldHeart's overall
business, as well as other statements that can be identified by
the use of forward-looking language, such as "believes,"
"feels," "expects," "may," "will," "should," "seeks," "plans,"
"anticipates," or "intends" or the negative of those terms, or
by discussions of strategy or intentions. Investors are
cautioned that all forward-looking statements involve risk and
uncertainties, including without limitation: risks involved in
the clinical trials of the Levacor VAD; WorldHeart's need for
additional capital in the future; risks in product development,
regulatory approvals and market acceptance of and demand for
WorldHeart's products; and other risks detailed in WorldHeart's
filings with the U.S. Securities and Exchange Commission,
including without limitation its Annual Report on Form 10-K for
the year ended December 31, 2009.
Source
World Heart Corporation |